Targeted PLGA-Microparticles as a Novel Concept for Treatment of Lactose Intolerance
Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Life Sciences, University of Vienna, Vienna, Austria
*
Author to whom correspondence should be addressed.
#
These authors equally contributed to this work.
Sci. Pharm. 2010, 78(3), 559; https://doi.org/10.3797/scipharm.cespt.8.LDD05
Submission received: 12 July 2010
/
Accepted: 12 July 2010
/
Published: 12 July 2010
Abstract
Background: Lactose intolerance is the inability to metabolize lactose because of the absence of the enzyme lactase. It is estimated that 75–90% of birth lactase levels are lost by most people after weaning. [...]
Share and Cite
MDPI and ACS Style
WANG, X.; RATZINGER, G.; WIRTH, M.; GABOR, F. Targeted PLGA-Microparticles as a Novel Concept for Treatment of Lactose Intolerance. Sci. Pharm. 2010, 78, 559. https://doi.org/10.3797/scipharm.cespt.8.LDD05
AMA Style
WANG X, RATZINGER G, WIRTH M, GABOR F. Targeted PLGA-Microparticles as a Novel Concept for Treatment of Lactose Intolerance. Scientia Pharmaceutica. 2010; 78(3):559. https://doi.org/10.3797/scipharm.cespt.8.LDD05
Chicago/Turabian StyleWANG, X., G. RATZINGER, M. WIRTH, and F. GABOR. 2010. "Targeted PLGA-Microparticles as a Novel Concept for Treatment of Lactose Intolerance" Scientia Pharmaceutica 78, no. 3: 559. https://doi.org/10.3797/scipharm.cespt.8.LDD05
